Peter Attia· MD
essentially the PSA went down by 50% and what they saw was the radiographic disease met went down by 50%
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
essentially the PSA went down by 50% and what they saw was the radiographic disease met went down by 50%
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
in 2015 the Hopkins group published a very interesting study on a concept called bipolar Androgen therapy they called it bat who was the lead on that uh it's schwartzer and the the senior was denmead and so in 2015 and I did something very unconventional you walk in with metastatic prostate cancer into Hopkins and what they do is they give you high doses of testosterone to treat your metastatic prostate cancer which is mind-boggling because the standard care for that patient is the exact opposite right it's to give you Androgen deprivation it's too chemically castrated right and the way they would do it they would give you Lupron first to shut you down and then they would give you high doses 400 milligrams every month and it would go up and down and it would basically convert the cast rate resistant prostate cancer to castrate it's a sensitive right and so and so essentially the PSA went down by 50 and what they saw was a radiographic disease went down by 50